Heart transplantation research in the next decade--a goal to achieving evidence-based outcomes: National Heart, Lung, And Blood Institute Working Group.

The National Heart, Lung, and Blood Institute (NHLBI) convened a Working Group (WG) on August 5 to 6, 2010 in Bethesda, Maryland to discuss future directions of research in heart transplantation (HT). The WG was composed of researchers with expertise in the basic science, clinical science, and epidemiological aspects of advanced heart failure and HT. These experts were asked to identify the highest priority research gaps in the field and make recommendations for future research strategies. The WG was also asked to include approaches that capitalize on current scientific opportunities and focus on areas that required unique NHLBI leadership. Finally, the WG was charged with developing recommendations that would have short- and long-term impact on the field of HT. The WG participants reviewed key areas in HT and identified the most urgent knowledge gaps. These gaps were then organized into the following 4 specific research directions: 1) enhanced phenotypic characterization of the pre-transplant population; 2) donor-recipient optimization strategies; 3) individualized immunosuppression therapy; and, 4) investigations of immune and non-immune factors affecting late cardiac allograft outcomes. Finally, because the HT population is relatively small compared with other patient groups, the WG strongly urged concerted efforts to enroll every transplant recipient into a clinical study and to increase collaborative networks to optimize research in this field.

[1]  P. Sinha,et al.  Do donor characteristics really matter? Short- and long-term impact of donor characteristics on recipient survival, 1995-1999. , 2002, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[2]  R. Jennings,et al.  Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. , 1986, Circulation.

[3]  S. Hunt,et al.  The changing face of heart transplantation. , 2008, Journal of the American College of Cardiology.

[4]  A. Kfoury,et al.  Controversies in defining cardiac antibody-mediated rejection: need for updated criteria. , 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[5]  M. Mehra,et al.  Current and future challenges in therapy for antibody-mediated rejection. , 2011, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[6]  Ranjit John,et al.  Outcomes in cardiac transplant recipients using allografts from older donors versus mortality on the transplant waiting list; Implications for donor selection criteria. , 2004, Journal of the American College of Cardiology.

[7]  J. Peart,et al.  Sustained cardioprotection: exploring unconventional modalities. , 2008, Vascular pharmacology.

[8]  L. Sharples,et al.  Deposition of C4d and C3d in cardiac transplants: a factor in the development of coronary artery vasculopathy. , 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[9]  M. Dew,et al.  Pulsatile left ventricular assist device support as a bridge to decision in patients with end-stage heart failure complicated by pulmonary hypertension. , 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[10]  C. Porter,et al.  Matching the heart donor and heart transplant recipient. Clues for successful expansion of the donor pool: a multivariable, multiinstitutional report. The Cardiac Transplant Research Database Group. , 1994, The Journal of Heart and Lung Transplantation.

[11]  J. Losman The International Society for Heart Transplantation , 1982 .

[12]  C. F. Wong,et al.  Cardiorenal syndrome - a new classification and current evidence on its management. , 2010, Clinical nephrology.

[13]  N. Smedira,et al.  The effect of combined Angiotensin-converting enzyme inhibition and calcium antagonism on allograft coronary vasculopathy validated by intravascular ultrasound. , 2005, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[14]  F. Pagani,et al.  Left ventricular assist device therapy improves utilization of donor hearts. , 2002, Journal of the American College of Cardiology.

[15]  M. Mehra,et al.  An intravascular ultrasound study of the influence of angiotensin-converting enzyme inhibitors and calcium entry blockers on the development of cardiac allograft vasculopathy. , 1995, The American journal of cardiology.

[16]  A. Kfoury,et al.  Temporal trends in heart transplantation from high-risk donors: are there lessons to be learned? A multi-institutional analysis. , 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[17]  A. Rahmel,et al.  The Registry of the International Society for Heart and Lung Transplantation: twenty-seventh official adult heart transplant report--2010. , 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[18]  G. Fonarow,et al.  Use of two recipient lists for adults requiring heart transplantation. , 2003, The Journal of thoracic and cardiovascular surgery.

[19]  D. Zimpfer,et al.  Post-transplant survival after lowering fixed pulmonary hypertension using left ventricular assist devices. , 2007, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[20]  M. Fishbein,et al.  Asymptomatic antibody-mediated rejection after heart transplantation predicts poor outcomes. , 2009, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[21]  R. Patten,et al.  The effect of ventricular assist devices on post-transplant mortality an analysis of the United network for organ sharing thoracic registry. , 2009, Journal of the American College of Cardiology.

[22]  A. Jatene,et al.  Prostacyclin in the management of pulmonary hypertension after heart transplantation. , 1990, The Journal of heart transplantation.

[23]  D. Holmes,et al.  Association of angiotensin-converting enzyme inhibitors and serum lipids with plaque regression in cardiac allograft vasculopathy. , 2006, Transplantation.

[24]  A. Dipchand,et al.  Minimizing infection and rejection death: clues acquired from 19 years of multi-institutional cardiac transplantation data. , 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[25]  A. Khaghani,et al.  Transplantation using hearts from primary pulmonary hypertensive donors for recipients with a high pulmonary vascular resistance. , 2004, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[26]  H. Bittner,et al.  Hemodynamic and inotropic effects of milrinone after heart transplantation in the setting of recipient pulmonary hypertension. , 1998, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[27]  D. Renlund,et al.  Cardiovascular mortality among heart transplant recipients with asymptomatic antibody-mediated or stable mixed cellular and antibody-mediated rejection. , 2009, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[28]  A. Angelini,et al.  Report from a consensus conference on antibody-mediated rejection in heart transplantation. , 2011, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[29]  M. Mehra,et al.  Presence of severe intimal thickening by intravascular ultrasonography predicts cardiac events in cardiac allograft vasculopathy. , 1995, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[30]  G. Faggian,et al.  Impact of donor quality on outcome of heart transplantation. , 2010, European Journal of Cardio-Thoracic Surgery.

[31]  A. Kfoury,et al.  Changing outcomes in patients bridged to heart transplantation with continuous- versus pulsatile-flow ventricular assist devices: an analysis of the registry of the International Society for Heart and Lung Transplantation. , 2011, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[32]  Clive Lewis,et al.  The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. , 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[33]  E. Tuzcu,et al.  Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. , 2003, The New England journal of medicine.